CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

The aims of this study were

• to analyze CD160 expression in both normal and pathological eyes from human adults
• to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.

CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

inclusion criteria :

• Patients with retinal surgery
• Patients who agree to participate to the study
• Major patient

exclusion criteria :

• Patient under law protection
• Minor patient